Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1989 1
1990 2
1991 2
1992 2
1993 1
1994 1
1995 1
1996 3
1997 2
1998 4
1999 4
2000 8
2001 5
2002 4
2003 9
2004 10
2005 12
2006 19
2007 14
2008 17
2009 10
2010 17
2011 16
2012 20
2013 25
2014 23
2015 22
2016 31
2017 28
2018 29
2019 29
2020 28
2021 30
2022 30
2023 25
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Lung Small Cell Carcinoma"
Page 1
DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. Owen DH, et al. J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. J Hematol Oncol. 2019. PMID: 31215500 Free PMC article. Review.
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. ...Here, we review the preclinical and clinical evidence for targeting DLL3 in SCLC and discuss several DLL3-specific therapies being developed for the treatment of SCLC: …
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. ...Here, we review the preclin …
Current Diagnosis and Management of Small-Cell Lung Cancer.
Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Wang S, et al. Mayo Clin Proc. 2019 Aug;94(8):1599-1622. doi: 10.1016/j.mayocp.2019.01.034. Mayo Clin Proc. 2019. PMID: 31378235 Review.
Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics from non-small-cell lung cancer. ...Immunotherapy, including nivolumab with or without ipilimumab, is now available …
Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characterist …
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, Deng Y, Zhu XQ, Liu H, Pan HX, Yang L, Bai HS, Luo X, Guo Y, Zhou MX, Sun YM, Zhang ZC, Li SM, Cheng X, Tan BX, Han LF, Liu YY, Zhang K, Zeng FX, Jia L, Hao XB, Wang YY, Feng G, Xie K, Lu Y, Zeng M. Wang XS, et al. J Natl Cancer Inst. 2023 Jun 8;115(6):742-748. doi: 10.1093/jnci/djac015. J Natl Cancer Inst. 2023. PMID: 35094066 Free PMC article. Clinical Trial.
BACKGROUND: Adding radiotherapy (RT) to systemic therapy improves progression-free survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer (NSCLC). Whether these findings translate to epidermal growth factor receptor (EGFR)-muta …
BACKGROUND: Adding radiotherapy (RT) to systemic therapy improves progression-free survival (PFS) and overall survival (OS) in oligometastat …
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells.
Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA. Li H, et al. Cell Rep Med. 2022 Mar 15;3(3):100554. doi: 10.1016/j.xcrm.2022.100554. eCollection 2022 Mar 15. Cell Rep Med. 2022. PMID: 35492873 Free PMC article.
Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor patient responses to immune checkpoint blockade (ICB), and introduction of a Stk11/Lkb1 (L) mutation into murine lung adenocarcinomas driven by mutant Kras and Trp53 …
Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor patient responses to immune chec …
Pembrolizumab-induced agranulocytosis.
Fernández Martínez V, García-Avello Fernández-Cueto A, Valencia Soto CM, Barbadillo Villanueva S, Ochagavía Sufrategui M, Rioja Carrera M, Alonso Buznego LA, Valero Domínguez M. Fernández Martínez V, et al. J Oncol Pharm Pract. 2024 Jun;30(4):767-771. doi: 10.1177/10781552241228774. Epub 2024 Jan 30. J Oncol Pharm Pract. 2024. PMID: 38291678
CASE REPORT: We report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stage IVB with programmed death-ligand 1 70% who developed agranulocytosis 10 days after a single dose of pembrolizumab as monotherapy. ...The main approach for agranulo …
CASE REPORT: We report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stage IVB with programmed dea …
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA. Pietanza MC, et al. J Clin Oncol. 2018 Aug 10;36(23):2386-2394. doi: 10.1200/JCO.2018.77.7672. Epub 2018 Jun 15. J Clin Oncol. 2018. PMID: 29906251 Free PMC article. Clinical Trial.
Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month pr …
Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer …
Small Cell Lung Cancer: Advances in Diagnosis and Management.
Chauhan AF, Liu SV. Chauhan AF, et al. Semin Respir Crit Care Med. 2020 Jun;41(3):435-446. doi: 10.1055/s-0039-1700566. Epub 2020 May 25. Semin Respir Crit Care Med. 2020. PMID: 32450596 Review.
Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by rapid growth and early spread. It is a highly lethal disease that typically is diagnosed at a late stage. Surgery plays a very small role in this cancer, and …
Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by rapid growth and early sp …
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. Goldsmith KC, et al. Nat Med. 2023 May;29(5):1092-1102. doi: 10.1038/s41591-023-02297-5. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012551 Free PMC article. Clinical Trial.
We conducted a first-in-child study evaluating lorlatinib with and without chemotherapy in children and adults with relapsed or refractory ALK-driven neuroblastoma. The trial is ongoing, and we report here on three cohorts that have met pre-specified primary endpoints: lor …
We conducted a first-in-child study evaluating lorlatinib with and without chemotherapy in children and adults with relapsed or refractor …
NUT carcinoma of the lung.
Lantuejoul S, Pissaloux D, Ferretti GR, McLeer A. Lantuejoul S, et al. Semin Diagn Pathol. 2021 Sep;38(5):72-82. doi: 10.1053/j.semdp.2021.06.005. Epub 2021 Jun 16. Semin Diagn Pathol. 2021. PMID: 34176698 Review.
This technique offers 87% sensitivity and nearly 100% specificity with reference to FISH or RT-PCR, which confirm the NUTM1 rearrangement. The differential diagnoses include basaloid carcinoma of the lung, small cell carcinoma, thymic carcino …
This technique offers 87% sensitivity and nearly 100% specificity with reference to FISH or RT-PCR, which confirm the NUTM1 rearrangement. T …
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.
Uras IZ, Moll HP, Casanova E. Uras IZ, et al. Int J Mol Sci. 2020 Jun 17;21(12):4325. doi: 10.3390/ijms21124325. Int J Mol Sci. 2020. PMID: 32560574 Free PMC article. Review.
Lung cancer is the most frequent cancer with an aggressive clinical course and high mortality rates. ...The disease has a complex and heterogeneous background with non-small-cell lung cancer (NSCLC) accounting for 85% of patients and lung adenoc …
Lung cancer is the most frequent cancer with an aggressive clinical course and high mortality rates. ...The disease has a complex and …
435 results